{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T01:40:09Z","timestamp":1684806009712},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2008,12,19]],"date-time":"2008-12-19T00:00:00Z","timestamp":1229644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s00520-008-0562-6","type":"journal-article","created":{"date-parts":[[2008,12,18]],"date-time":"2008-12-18T04:37:38Z","timestamp":1229575058000},"page":"735-744","source":"Crossref","is-referenced-by-count":2,"title":["Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center"],"prefix":"10.1007","volume":"17","author":[{"given":"Amy P.","family":"Abernethy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally Y.","family":"Barbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hope","family":"Uronis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Yousuf","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"April","family":"Coan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary Ruth","family":"Pupa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane L.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Herndon II","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,19]]},"reference":[{"key":"562_CR1","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511527081","volume-title":"The cancer chemotherapy handbook","author":"DS Fischer","year":"2003","unstructured":"Fischer DS, Durivage HJ, Knobf MT et al (2003) The cancer chemotherapy handbook, 6th edn. Mosby, St. Louis, MO","edition":"6"},{"key":"562_CR2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1634\/theoncologist.10-6-427","volume":"10","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Lyman CH, Agboola O (2005) Risk models for predicting chemotherapy-induced neutropenia. Oncologist 10:427\u2013437. doi: 10.1634\/theoncologist.10-6-427","journal-title":"Oncologist"},{"key":"562_CR3","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","volume":"64","author":"GP Bodey","year":"1966","unstructured":"Bodey GP, Buckley M, Sathe YS et al (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328\u2013340","journal-title":"Ann Intern Med"},{"key":"562_CR4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0014-2964(73)90007-8","volume":"9","author":"J Klastersky","year":"1973","unstructured":"Klastersky J, Weerts D, Hensgens C et al (1973) Fever of unexplained origin in patients with cancer. Eur J Cancer 9:649\u2013656. doi: 10.1016\/0014-2964(73)90007-8","journal-title":"Eur J Cancer"},{"key":"562_CR5","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/1097-0142(196011\/12)13:6<1240::AID-CNCR2820130613>3.0.CO;2-9","volume":"13","author":"DR Boggs","year":"1960","unstructured":"Boggs DR, Frei E (1960) Clinical studies of fever and infection in cancer. Cancer 13:1240\u20131253. doi: 10.1002\/1097-0142(196011\/12)13:6<1240::AID-CNCR2820130613>3.0.CO;2-9","journal-title":"Cancer"},{"key":"562_CR6","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258\u20132266. doi: 10.1002\/cncr.21847","journal-title":"Cancer"},{"key":"562_CR7","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205. doi: 10.1200\/JCO.2006.06.4451","journal-title":"J Clin Oncol"},{"key":"562_CR8","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1185\/030079907X219599","volume":"23","author":"L Pinto","year":"2007","unstructured":"Pinto L, Liu Z, Doan Q et al (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283\u20132295. doi: 10.1185\/030079907X219599","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 1","key":"562_CR9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/00003495-200262001-00005","volume":"62","author":"GH Lyman","year":"2002","unstructured":"Lyman GH, Kuderer NM, Lyman GH et al (2002) Filgrastim in patients with neutropenia: potential effects on quality of life. Drugs 62(Suppl 1):65\u201378. doi: 10.2165\/00003495-200262001-00005","journal-title":"Drugs"},{"key":"562_CR10","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178\u20131184. doi: 10.1200\/JCO.2005.09.102","journal-title":"J Clin Oncol"},{"key":"562_CR11","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1200\/JCO.2004.00.7955","volume":"23","author":"JN Timmer-Bonte","year":"2005","unstructured":"Timmer-Bonte JN, de Boo TM, Smit HJ et al (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23:7974\u20137984. doi: 10.1200\/JCO.2004.00.7955","journal-title":"J Clin Oncol"},{"key":"562_CR12","unstructured":"American Society of Clinical Oncology (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Accessed online May 27, 2008"},{"key":"562_CR13","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","volume":"42","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433\u20132453. doi: 10.1016\/j.ejca.2006.05.002","journal-title":"Eur J Cancer"},{"key":"562_CR14","unstructured":"NCCN (2008) Clinical Practice Guidelines in Oncology Myeloid Growth Factors. National Comprehensive Cancer Network V.1.2008"},{"key":"562_CR15","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB et al (2000) The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038\u20133051","journal-title":"J Clin Oncol"},{"key":"562_CR16","first-page":"555","volume":"12","author":"A Uys","year":"2004","unstructured":"Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555\u2013560. doi: 10.1007\/s00520-004-0614-5","journal-title":"Support Care Cancer"},{"key":"562_CR17","doi-asserted-by":"crossref","unstructured":"Dale DC, Cosler LE, Wolf D et al Poster 6107: Economic analysis of prophylactic granulocyte colony-stimulating factor use based on a risk model for neutropenic complications in breast cancer patients receiving adjuvant chemotherapy. American Society of Clinical Oncology Annual Meeting. Atlanta, GA, 2006","DOI":"10.1200\/jco.2006.24.18_suppl.6107"},{"key":"562_CR18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1592\/phco.24.5.488.33360","volume":"24","author":"LE Cosler","year":"2004","unstructured":"Cosler LE, Calhoun EA, Agboola O et al (2004) Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 24:488\u2013494. doi: 10.1592\/phco.24.5.488.33360","journal-title":"Pharmacotherapy"},{"key":"562_CR19","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1200\/JCO.2005.05.645","volume":"23","author":"OAC Clark","year":"2005","unstructured":"Clark OAC, Lyman GH, Castro AA et al (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198\u20134214. doi: 10.1200\/JCO.2005.05.645","journal-title":"J Clin Oncol"},{"key":"562_CR20","unstructured":"Lyman GH, Kuderer NM, Crawford J et al (2008) Prospective validation of a risk model for first cycle neutropenic complications in patients receiving cancer chemotherapy. J. Clin. Oncol., 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition), pp 8561"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-008-0562-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-008-0562-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-008-0562-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T01:13:46Z","timestamp":1684804426000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-008-0562-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,19]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["562"],"URL":"https:\/\/doi.org\/10.1007\/s00520-008-0562-6","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,19]]}}}